Alkermes plc Stock News

The drugmaker beat Wall Street's expectations with its Q1 results.

Alkermes (ALKS) delivered earnings and revenue surprises of 1,100% and 6.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.

Alkermes (NASDAQ:ALKS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 2 0 0 Last 30D 0 0

Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone to treat schizophrenia faces rejection from the FDA.

Upgrades For Avis Budget Group Inc (NASDAQ:CAR), Barclays upgraded the previous rating of Underweight to Equal-Weight. In the fourth quarter, Avis Budget Gr showed an EPS of $7.08, compared to $0.36 f

Alkermes is a publicly-traded company that offers biopharmaceutical products and technology. The company has seen a reduction in losses in the past few years and is making steady progress towards gene

Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant immunotherapy for advanced renal cell carcin

Alkermes plc (NASDAQ: ALKS ) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant immunotherapy for advanced renal cell carcinoma (RCC). The data were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium. The presentation includes updated efficacy and safety data from the monotherapy arm of ARTISTRY-1, in which … Full story available on Benzinga.com

Alkermes (ALKS) rides high on both earnings and sales beating estimates in the fourth quarter of 2021.

Alkermes (ALKS) rides high on both earnings and sales beating estimates in the fourth quarter of 2021.

Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant immunotherapy for advanced renal cell carcin

The biotech smashed analyst estimates in its final quarter of 2021.